Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation [4]

Annals of Hematology

Volumn 85, Issue 8, 2006, Pages 549-551

  Tosi, Patrizia ^a,b   Zamagni, Elena ^a   Cangini, Delia ^a   Tacchetti, Paola ^a   Perrone, Giulia ^a   Ceccolini, Michela ^a   Baccarani, Michele ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; COUGHING; DYSPNEA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; THROMBOCYTOPENIA;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; GRAFT SURVIVAL; HUMANS; MALE; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747826343     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0111-7     Document Type: Letter

References (10)

1. Cavo M, Terragna C, Martinelli G et al (2000) Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 96:355-357
2. Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J (2004) Donor lymphocyte infusions for multiple myeloma: Clinical results and novel perspectives. Bone Marrow Transplant 34:923-928
3. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al (2005) Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: A retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 35:165-169
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
5. Giralt S, Aleman A, Lei X, Davis M, Mickler K, Weber D et al (2004) Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after anallogeneic transplant. Preliminary results show efficacy without induction of GVHD. Blood 104:1651a
6. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R (2005) Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 90:278-279
7. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 15(101):2377-2380
8. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172
9. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H et al (2004) Inhibition of acute graft versus host disease with retention of graft versus tumor effect by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101:8120-8125
10. Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR et al (2005) Differential effects of proteasome inhibition by bortezomib on murine acute graft versus host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 106:3293-3299